Analysts Raise Zymeworks Target on Pipeline Progress While Weighing Risks and Valuation Changes

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

25 Mar 25

Updated

04 Dec 25

Views

71

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

81.3%

7D

-1.2%

Loading

1Y

81.3%

7D

-1.2%

You can edit this narrative until Dec 5 5:10 AM. Then, changes will post as Updates.

Author's Valuation

US$34.523.1% undervalued

AnalystConsensusTarget Fair Value

Shared on 04 Dec 25

Fair value Increased 0.88%

ZYME: Royalty Model Will Benefit From Positive HER2 Gastric Cancer Data

Analysts nudged their fair value estimate for Zymeworks slightly higher, from $34.20 to $34.50. This reflects growing confidence that the company’s shift toward a royalty aggregator model, coupled with strong HERIZON-GEA-01 data for Ziihera and encouraging early ZW191 results, can drive faster revenue growth and improved profitability.

Shared on 20 Nov 25

Fair value Increased 40%

ZYME: Recurring Royalty Revenue Will Drive Momentum After Positive Clinical Results

Zymeworks' analyst price target has surged from approximately $24.45 to $34.20 per share. This increase reflects analysts' optimism following the company's positive clinical trial results and strategic shift toward generating recurring royalty revenues.

Shared on 05 Nov 25

Fair value Increased 3.26%

ZYME: Encouraging Pipeline Data Will Drive Momentum Ahead Of Key Clinical Readouts

Analysts have raised their price target for Zymeworks from $23.68 to $24.45 per share. They cite increased confidence in the company's growth outlook following encouraging clinical data and expanding therapeutic opportunities.

Shared on 22 Oct 25

Fair value Increased 10%

Analysts have increased their price target for Zymeworks from $21.45 to $23.68 per share. They cite the company's differentiated therapies and upcoming clinical milestones as key drivers for the revised outlook.

Shared on 08 Oct 25

Fair value Increased 6.95%

Analysts have increased their price target for Zymeworks from $20.06 to $21.45, citing improving revenue growth forecasts, stronger projected profit margins, and growing confidence in the momentum of Zanidatamab in biliary tract cancer. Analyst Commentary Recent commentary from street research reflects a mix of optimism and caution surrounding Zymeworks, particularly as the company advances its lead asset, Zanidatamab, in the biliary tract cancer market.

Shared on 20 Sep 25

Fair value Decreased 4.72%

Despite raised analyst confidence driven by positive clinical momentum for Zanidatamab and anticipated catalysts, Zymeworks’ consensus analyst price target has been modestly lowered from $21.05 to $20.06. Analyst Commentary Positive momentum for Zanidatamab in biliary tract cancer.

Shared on 01 May 25

Fair value Decreased 19%

Shared on 24 Apr 25

Fair value Increased 20%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

Fair value Decreased 17%

Shared on 09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 20%

AnalystConsensusTarget has increased revenue growth from 12.4% to 16.9%, increased profit margin from 10.5% to 19.3%, decreased future PE multiple from 120.8x to 71.9x and increased shares outstanding growth rate from -0.0% to -0.0%.

AnalystConsensusTarget Fair Value

US$34.5

23.1% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

20.87%

Biotech revenue growth rate

8.46%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

7.02%

Calculation

US$8.98m

Earnings '28

x

428.52x

PE Ratio '28

=

US$3.85b

Market Cap '28

US$3.85b

Market Cap '28

/

91.68m

No. shares '28

=

US$41.99

Share Price '28

US$41.99 Share Price '28

Discounted to 2025 @ 7.03% p.a.

=

US$34.24

Fair Value '25